You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《异动股》复星医药(02196.HK)倒跌6% 曾考验10天线
阿思达克 07-28 10:49
美国政府上周斥19.5亿美元购买辉瑞与德国生物科技公司BioNTech研发1亿剂新冠肺炎疫苗。由於BioNTech是复星医药(02196.HK)战略合作夥伴,消息刺激後者股价近日反覆探顶,昨天曾升至39.5元,受制上周五盘中所创近两年高位40.15元,今天股价高开升至39元无以为继,掉头考验10天线(35.16元)支持,最低见35.1元,现造35.9元,倒跌5.9%,成交1,135万股,涉资4.15亿元。

复星医药(600196.SH)昨天收市後,就A股於上周四至本周一连续三个交易日收市价升幅均偏离累计超过20%发声明指,集团不存在披露而未披露的重大信息。至於公司控股子公司上海复生医药产业发展BioNTech许可的用於预防新冠肺炎的mRNA疫苗虽然已获中国国家药品监督管理局批准於内地开展临床试验,但由於该疫苗还尚处於I期临床试验启动阶段,根据目前内地关於疫苗产品的审批要求及研发经验,该疫苗尚需完成临床I期、II期及III期试验,上市批准及生产设施认证/核查(如适用)等主要环节且受到诸多不确定因素影响。因此,该疫苗在内地能否获得相关药品监管机构上市批准及上市批准时间等方面存在不确定性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account